AURORA, Ontario, Sept. 23 /PRNewswire/ -- Helix BioPharma announced today that Dr. Heman Chao, Vice President of Research at Helix BioPharma Corp., will be presenting L-DOS47 research findings at the National Research Council of Canada's (NRC) Eighth Annual General Meeting of the Genomics and Health Initiative, today in Saskatoon, Saskatchewan, Canada. The meeting includes Canadian researchers from across the NRC, government departments and private industry and covers diverse topics in genomics research.
Dr. Chao's presentation, titled "L-DOS47: Targeting the Tumor Microenvironment with an Immunoconjugate" will provide a summary of selected previously announced L-DOS47 research findings. "We are very pleased to have been invited to participate in this important scientific forum," said Dr. Chao. "It is an excellent opportunity to showcase our findings to Canada's research community as we continue to advance our L-DOS47 development program.
For additional information on the Genomics and Health Initiative conference, please visit: http://www.pbi.nrc.ca/ghi-agm.htm .
L-DOS47 combines Helix's proprietary DOS47 new drug candidate with a highly specific single domain antibody, to form a potential new targeted drug product for the treatment of adenocarcinoma of the lung, the most common form of cancer in the world today. L-DOS47 is thought to function by leveraging a natural process in the body called the urea cycle, to produce an anti-cancer effect. It is based upon a naturally occurring enzyme called urease that essentially reverses the urea cycle by breaking down urea into metabolites that include ammonia and hydroxyl ions. By doing so at the site of cancerous tissues in the body, L-DOS47 is believed to modify the microenvironmental conditions of lung cancer cells in a manner that leads to their death. Among these theorized effects, L-DOS47 is believed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra-cellular conditions that are known to be necessary for cancer cell survival. As well, the local production of ammonia at the site of cancerous tissues is thought to readily diffuse into the cancer cells to exert a potent cytotoxic effect by interfering with their critical metabolic functions.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in
the field of cancer therapy. The Company is actively developing innovative
products for the prevention and treatment of cancer based on its
proprietary technologies. Helix's product development initiatives include
its Topical Interferon Alpha- 2b and its novel L-DOS47 new drug candidate.
Helix is listed on the TSX under the symbol "HBP".
For further information contact:
Investor & Media Relations
Russo Partners LLC
Tel: (619) 814-3510
Fax: (619) 955-5318
Russo Partners LLC
Tel: (212) 845-4271
Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains certain forward-looking statements and information regarding the Company's activities, which statements and information can be identified by the use of forward-looking terminology such as "believed", "continue", "developing", "potential", or variations thereon, or comparable terminology referring to future events or results. Forward looking statements and information are statements and information about the future and are inherently uncertain. Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks and uncertainties including without limitation: uncertainty whether L-DOS47 will be successfully developed and commercialized as a drug or at all; the need for additional clinical trials, the occurrence and success of which cannot be assured; product liability and insurance risks; research and development risks, the risk of technical obsolescence; the need for further regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix's products; as well as a description of other risks and uncertainties affecting Helix and its business, as contained in news releases and filings with the Canadian Securities Regulatory Authorities, including its latest Annual Information Form, at http://www.sedar.com, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements and information are based on the beliefs, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, opinions or expectations, or other circumstances change, except as required by law.
|SOURCE Helix BioPharma|
Copyright©2008 PR Newswire.
All rights reserved